Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

EULAR 2020 E-Congress

Top trending from EULAR 2020 E-Congress

COVID-19 hospitalization: What do the data tell us?

A round-up of the data presented at the EULAR 2020 E-Congress with additional commentary provided by Pedro Machado.

SELECT-CHOICE study results

The latest news on upadacitinib versus abatacept in this head-to-head rheumatoid arthritis trial.

SELECT-PsA-1 and SELECT-PsA-2: Upadacitinib shows promise for PsA

The latest news on these trials with additional commentary provided by Alexis Ogdie and lead investigator Philip Mease. 

Congress highlights from the Editorial Board

12-06-2020 | EULAR 2020 | Conference coverage | Video

EULAR 2020 highlights: Fernando Pérez-Ruiz

Fernando Pérez-Ruiz discusses some of the key gout and crystal arthritis studies presented at the EULAR 2020 E-Congress (8:10).

10-06-2020 | EULAR 2020 | Conference coverage | Video

EULAR 2020 highlights: Oliver FitzGerald

Oliver FitzGerald outlines his highlights from the psoriatic arthritis presentations at the EULAR 2020 E-Congress, and discusses what the study results mean for clinical practice (10:13).

Latest news from EULAR 2020 E-Congress

12-06-2020 | EULAR 2020 | Conference coverage | News

Biologic, targeted synthetic DMARDs linked to increased herpes zoster risk

11-06-2020 | EULAR 2020 | Conference coverage | News

Quantitative computed tomography predicts 10-year mortality risk in SSc–ILD

10-06-2020 | EULAR 2020 | Conference coverage | News

EQUATOR biomarker analysis supports anti-inflammatory action of filgotinib in PsA

10-06-2020 | EULAR 2020 | Conference coverage | News

No impact of metformin on gout outcomes in people with diabetes

09-06-2020 | EULAR 2020 | Conference coverage | News

Artificial intelligence accurately determines osteoarthritis stage

09-06-2020 | EULAR 2020 | Conference coverage | News

Guselkumab benefits maintained over 1 year in patients with PsA

08-06-2020 | EULAR 2020 | Conference coverage | News

Methotrexate unlikely to exacerbate risk for ILD in RA patients

08-06-2020 | EULAR 2020 | Conference coverage | News

Sustained benefits with secukinumab in nonradiographic axial spondyloarthritis

08-06-2020 | EULAR 2020 | Conference coverage | News

No benefit of therapeutic drug monitoring in patients starting infliximab therapy

08-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib outperforms abatacept in head-to-head RA trial
View all EULAR 2020 E-Congress news

Expert interviews from EULAR 2020 E-Congress

09-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The JAKPOT study

Kim Lauper discusses findings from the JAKPOT study, an international collaboration showing comparable JAK inhibitor and TNF inhibitor retention rates in real-world patients with rheumatoid arthritis (3:50).

09-06-2020 | EULAR 2020 | Conference coverage | Video

Expert commentary: The SELECT-PsA-1 and SELECT-PsA-2 trials

Alexis Ogdie comments on the results of two phase 3 trials demonstrating the potential of upadacitinib as a treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents (3:59).

06-06-2020 | EULAR 2020 | Conference coverage | Video

Expert commentary: VTE in patients with RA

John Isaacs comments on two studies on venous thromboembolism in patients with rheumatoid arthritis, highlighting the robustness of the findings and what they mean for patient management (5:47).

03-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: TNF inhibitors linked to reduced VTE risk in RA patients

04-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The CONTROL trial

04-06-2020 | EULAR 2020 conference hub | Conference coverage | Video

Expert commentary: The EXCEED trial

04-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The ADVOCATE trial

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The EXCEED trial

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: The BLISS-LN trial

05-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-1

06-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: SELECT-PsA-2

06-06-2020 | EULAR 2020 | Conference coverage | Video

Researcher comment: COVID-19 risk factors in RMD patients


Medicine Matters conference coverage is brought to you in partnership with medwireNews


Image Credits